Beauty Health Company Rebrands to SkinHealth Systems
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy SKIN?
Beauty Health Company announced a corporate rebrand to SkinHealth Systems, marking its evolution into a clinically driven, science-backed medical aesthetics company. The company will operate under the new name effective immediately while continuing to trade on the Nasdaq Capital Market under the same ticker symbol, "SKIN." "This is not simply a change in name. It represents a fundamental evolution in how we operate, and how we intend to compete. Our focus is on building a durable, scalable ecosystem of skin health technologies and solutions that delivers consistent, provider-led outcomes and creates long-term value for our customers and stakeholders," said Pedro Malha, CEO of SkinHealth Systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SKIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SKIN
Wall Street analysts forecast SKIN stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 0.804
Low
1.60
Averages
1.63
High
1.65
Current: 0.804
Low
1.60
Averages
1.63
High
1.65
About SKIN
SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SkinHealth Systems to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: SkinHealth Systems will report its Q1 2026 financial results after market close on May 7, 2026, providing key financial metrics to assess the company's performance.
- Investor Conference Call: Following the earnings release, the company will host an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries to enhance transparency.
- Disclosure Channels: SkinHealth Systems discloses material information to the public through various means, including SEC filings, press releases, and conference calls, ensuring compliance with Regulation FD and enhancing corporate transparency.
- Company Overview: SkinHealth Systems is a global medical aesthetics company delivering clinically proven solutions, anchored by its leading Hydrafacial™ brand, committed to improving consumer skin health and providing quality treatment experiences.
See More
Beauty Health Company Q4 2025 Earnings Call Insights
- Revenue Performance: In Q4 2025, total revenue reached $82.4 million, reflecting a 1.3% year-over-year decline, yet showing significant improvement from the previous quarter's double-digit drop, with consumables revenue rising to $57.7 million, indicating resilience and potential in the market.
- Margin Improvement: The CFO reported an increase in adjusted gross margins from 62% to over 68%, while GAAP gross margins rose from 54.5% to 65.3%, demonstrating substantial progress in cost control and profitability.
- Future Outlook: For 2026, the company anticipates revenue between $285 million and $305 million, with expectations that the first half may be slightly below last year, but a recovery is expected in the second half, reflecting management's confidence in future growth.
- Strategic Focus: The CEO emphasized that 2026 will be an execution year, concentrating on sales force excellence, marketing discipline, and innovation, particularly the early development of the next-generation Hydrafacial system targeted for launch in 2028, aimed at enhancing market competitiveness.
See More
Beauty Health Q4 Earnings Report Analysis
- Earnings Performance: Beauty Health reported a Q4 GAAP EPS of -$0.06, missing expectations by $0.01, indicating challenges in profitability that could affect investor confidence.
- Revenue Figures: The company generated $82.4 million in revenue, a 1.3% year-over-year decline, although it beat market expectations by $4.28 million; however, the ongoing revenue decline may pressure future growth prospects.
- Market Reaction: The earnings miss may lead investors to question the company's future profitability, resulting in increased stock price volatility and impacting overall market confidence in Beauty Health.
- Strategic Implications: Despite exceeding revenue expectations, the persistent losses and declining revenue may prompt the company to reassess its market strategy to address challenges posed by intensified competition and changing consumer demands.
See More
Beauty Health (SKIN) Q4 Earnings Preview
- Earnings Announcement Date: Beauty Health (SKIN) is set to announce its Q4 earnings on March 12th after market close, with investors keenly awaiting its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a 37.5% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The consensus revenue estimate is $78.12 million, representing a 6.4% year-over-year decline, highlighting challenges and sales pressures faced by the company in a competitive market.
- Historical Performance Review: Over the past year, SKIN has exceeded EPS estimates 25% of the time and revenue estimates 75% of the time, suggesting a degree of capability to outperform expectations.
See More
Beauty Health Company to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: The Beauty Health Company (NASDAQ:SKIN) will release its fourth quarter and full year 2025 financial results after market close on March 12, 2026, providing investors with critical performance data and future outlook.
- Investor Conference Call: Following the earnings release, the company will host an investor conference call at 4:30 p.m. Eastern Time, aimed at discussing financial results and strategic direction in depth, enhancing transparency and communication.
- Webcast Access: Investors can access the live webcast of the conference call through the company's investor relations website, ensuring all stakeholders can obtain real-time information and improving the convenience of information disclosure.
- Compliance Disclosure: The Beauty Health Company discloses material information to the public through various channels, including SEC filings, press releases, and public conference calls, ensuring compliance with regulatory requirements and maintaining investor trust.
See More
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
See More
SkinHealth Systems to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: SkinHealth Systems will report its Q1 2026 financial results after market close on May 7, 2026, providing key financial metrics to assess the company's performance.
- Investor Conference Call: Following the earnings release, the company will host an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries to enhance transparency.
- Disclosure Channels: SkinHealth Systems discloses material information to the public through various means, including SEC filings, press releases, and conference calls, ensuring compliance with Regulation FD and enhancing corporate transparency.
- Company Overview: SkinHealth Systems is a global medical aesthetics company delivering clinically proven solutions, anchored by its leading Hydrafacial™ brand, committed to improving consumer skin health and providing quality treatment experiences.
See More
Beauty Health Company Q4 2025 Earnings Call Insights
- Revenue Performance: In Q4 2025, total revenue reached $82.4 million, reflecting a 1.3% year-over-year decline, yet showing significant improvement from the previous quarter's double-digit drop, with consumables revenue rising to $57.7 million, indicating resilience and potential in the market.
- Margin Improvement: The CFO reported an increase in adjusted gross margins from 62% to over 68%, while GAAP gross margins rose from 54.5% to 65.3%, demonstrating substantial progress in cost control and profitability.
- Future Outlook: For 2026, the company anticipates revenue between $285 million and $305 million, with expectations that the first half may be slightly below last year, but a recovery is expected in the second half, reflecting management's confidence in future growth.
- Strategic Focus: The CEO emphasized that 2026 will be an execution year, concentrating on sales force excellence, marketing discipline, and innovation, particularly the early development of the next-generation Hydrafacial system targeted for launch in 2028, aimed at enhancing market competitiveness.
See More
Beauty Health Q4 Earnings Report Analysis
- Earnings Performance: Beauty Health reported a Q4 GAAP EPS of -$0.06, missing expectations by $0.01, indicating challenges in profitability that could affect investor confidence.
- Revenue Figures: The company generated $82.4 million in revenue, a 1.3% year-over-year decline, although it beat market expectations by $4.28 million; however, the ongoing revenue decline may pressure future growth prospects.
- Market Reaction: The earnings miss may lead investors to question the company's future profitability, resulting in increased stock price volatility and impacting overall market confidence in Beauty Health.
- Strategic Implications: Despite exceeding revenue expectations, the persistent losses and declining revenue may prompt the company to reassess its market strategy to address challenges posed by intensified competition and changing consumer demands.
See More
Beauty Health (SKIN) Q4 Earnings Preview
- Earnings Announcement Date: Beauty Health (SKIN) is set to announce its Q4 earnings on March 12th after market close, with investors keenly awaiting its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a 37.5% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The consensus revenue estimate is $78.12 million, representing a 6.4% year-over-year decline, highlighting challenges and sales pressures faced by the company in a competitive market.
- Historical Performance Review: Over the past year, SKIN has exceeded EPS estimates 25% of the time and revenue estimates 75% of the time, suggesting a degree of capability to outperform expectations.
See More
Beauty Health Company to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: The Beauty Health Company (NASDAQ:SKIN) will release its fourth quarter and full year 2025 financial results after market close on March 12, 2026, providing investors with critical performance data and future outlook.
- Investor Conference Call: Following the earnings release, the company will host an investor conference call at 4:30 p.m. Eastern Time, aimed at discussing financial results and strategic direction in depth, enhancing transparency and communication.
- Webcast Access: Investors can access the live webcast of the conference call through the company's investor relations website, ensuring all stakeholders can obtain real-time information and improving the convenience of information disclosure.
- Compliance Disclosure: The Beauty Health Company discloses material information to the public through various channels, including SEC filings, press releases, and public conference calls, ensuring compliance with regulatory requirements and maintaining investor trust.
See More
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
See More
